Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate
Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate
Sangamo Therapeutics第四季度每股收益美元（0.34）未達到預期（0.26美元），銷售額204萬美元低於810萬美元的預期
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 6.25 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $2.04 million which missed the analyst consensus estimate of $8.10 million by 74.79 percent. This is a 92.50 percent decrease over sales of $27.23 million the same period last year.
Sangamo Therapeutics（納斯達克股票代碼：SGMO）公佈的季度虧損爲每股0.34美元，比分析師普遍預期的0.26美元（0.26美元）低30.77個百分點。與去年同期每股虧損0.32美元（0.32美元）相比，下降了6.25％。該公司公佈的季度銷售額爲204萬美元，比分析師普遍預期的810萬美元低74.79％。這比去年同期的2723萬美元的銷售額下降了92.50％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。